Update regarding AIM admission of RenalytixAI

 1st Nov 2018

Download the full announcement


EKF Diagnostics Holdings plc (AIM: EKF) announces that, further to the announcement on 31 October confirming that Renalytix AI plc (“RenalytixAI”) had successfully raised £22.25 million in gross proceeds, RenalytixAI will now be admitted to trading on AIM on 6 November 2018. An updated Schedule One announcement is expected to be issued on 2 November 2018.


Participants in the fundraising will be contacted by N+1 Singer, the Company or Link Asset Services to confirm updated settlement instructions.


EKF and N+1 Singer, the Company’s current nominated adviser and broker, have agreed that in order to preserve the independence of its nominated adviser, EKF will appoint a new nominated adviser after the admission of RenalytixAI.  A further announcement will be made in this regard in due course. 


N+1 Singer will continue to act as broker to EKF.



EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, FD and COO

Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker)

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303


About EKF Diagnostics Holdings plc www.ekfdiagnostics.com


 EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.